• Explore /
  • Poster
  • / Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or bev plus Cetux: Results from CALGB 80405 (Alliance).

Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or bev plus Cetux: Results from CALGB 80405 (Alliance).

Abstract Poster

Authors

Andrew Nixon

Andrew B. Nixon

Duke University Medical Center, Durham, NC

Andrew B. Nixon , Alexander Sibley , Ace Joseph Hatch , Yingmiao Liu , Chen Jiang , Flora Mulkey , Mark D. Starr , John C. Brady , Donna Niedzwiecki , Federico Innocenti , Alan P. Venook , Howard S. Hochster , Heinz-Josef Lenz , Bert H. O'Neil , Kouros Owzar , Herbert Hurwitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3597)

DOI

10.1200/JCO.2016.34.15_suppl.3597

Abstract #

3597

Poster Bd #

294

Abstract Disclosures

Similar Posters

First Author: Satoshi Yuki

First Author: Satoshi Yuki

First Author: Yu Sunakawa

First Author: Federico Innocenti